| Document |
Document Title |
|
WO/2011/053048A2 |
The present invention relates to a novel vascular leak inhibitor. The novel vascular leak inhibitor of the present invention inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by V...
|
|
WO/2011/053948A1 |
The present invention relates to compounds of the formula (I) wherein A, Y, Z, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the end...
|
|
WO/2011/048554A2 |
The present invention relates to the cosmetic use of a combination including a lysate of at least one probiotic microorganism of the Bifidobacterium sp. genus having at least one C-glycoside derivative as an active agent that can be used...
|
|
WO/2011/048148A2 |
This invention relates to compounds represented by formula (I) wherein the variables are defined as herein above, which are useful for treating diseases and conditions mediated by the sodium D-glucose co-transporter (SGLT), e.g. diabetes...
|
|
WO/2011/045478A1 |
The present invention relates to substrates coated with films including compounds having the following generic formula (I): formula (I) as well as the manufacturing method thereof and the use of same as an anode interfacial layer in elec...
|
|
WO/2011/043272A1 |
Disclosed are: a ligand for an asymmetric synthesis catalyst; and a process for producing an α-alkenyl cyclic compound using the ligand. Specifically disclosed are: a ligand for an asymmetric synthesis catalyst, which is represented by ...
|
|
WO/2011/040509A1 |
In order to provide a low molecular weight compound that has p38MAPK inhibitory activity and the accompanying TNFα production suppression activity and that has a favorable pharmacokinetic profile as a pharmaceutical and decreased hepato...
|
|
WO/2011/038926A1 |
A process for the protection of a compound having at least one reactive functional group selected from hydroxy, mercapto, carboxyl, amino and amide, with 3,4-dihydro-2H-pyran (DΗP), wherein said DΗP is obtained by contacting tetrahydro...
|
|
WO/2011/038910A1 |
The present invention relates to a process for the preparation of 2,3-dihydropyran (DHP, CAS [110-87-2]) and its use in industrial chemistry.
|
|
WO/2011/034078A1 |
Disclosed is a compound which is useful as the active ingredient of a medicinal composition, in particular, a medicinal composition for preventing and/or treating a VAP-1 associated disease. As the results of intensive studies on compoun...
|
|
WO/2011/030160A1 |
A method for determining the presence of mycobacteria species in an organism or biological sample, the method comprising adding to the organism or biological sample a probe molecule comprising a substrate and a label, which probe molecul...
|
|
WO/2011/030591A1 |
Disclosed is a novel zinc cluster compound represented by general formula (1): Zn4O(OCOR)6(RCOOH)n, wherein R represents an alkyl group which has 1 to 4 carbon atoms and may be substituted with a halogen atom, and n represents 0.1 to 1, ...
|
|
WO/2010/136431A9 |
The present invention provides compounds of formula (I) wherein the substituents are as defined in claim 1. The compounds are suitable intermediates in the preparation of herbicidally active 4-phenyl-3,5-pyrandiones, 4-phenyl-3,5-thiopyr...
|
|
WO/2011/027888A1 |
Disclosed are a diamide-phenyl derivative which inhibits soluble epoxy hydrolase (sEH), and a pharmaceutically acceptable salt of the diamide-phenyl derivative. Specifically disclosed are a compound represented by formula (I), and a phar...
|
|
WO/2011/021534A1 |
Provided are liquid crystal compounds which have large negative permittivity anisotropy and combine a high clearing point and a low viscosity and which further have at least one other characteristic such as heat or light stability, prope...
|
|
WO/2011/014008A2 |
The present invention relates to novel 3-phenoxy-4-pyrone, 3-phenoxy-4-pyridone, or 4-pyridone derivatives, or to pharmaceutically acceptable salts thereof, to a method for preparing same, and to an antibacterial composition containing s...
|
|
WO/2011/006208A1 |
The present invention relates to compounds that selectively inhibit influenza A virus group (1) sialidases and are therefore potential anti-influenza agents.
|
|
WO/2011/003976A1 |
The present invention relates to a crystallisation procedure to obtain 1 -(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thie
nylmethyl] benzene hemihydrate crystals having a narrow particle size distribution and improved flowabi...
|
|
WO/2010/151644A2 |
Disclosed is a general methodology to create nano fibers of therapeutic molecules that have a dual role, as both the delivery vehicle and the drug itself. It is shown that with proper molecular design, the integration of enzymatic reacti...
|
|
WO/2010/145788A1 |
The present invention relates to propargyloxybenzamide derivatives, their processes of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic ...
|
|
WO/2010/145789A1 |
The present invention relates to propargyloxybenzamide derivatives, their processes of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic ...
|
|
WO/2010/142650A1 |
The invention relates to compounds of formula (I) wherein A1, R1, R2, R3, R4 and R5 are defined in the description and in the claims, which are preferential inhibitors of the cysteine protease cathepsin, in particular of the cysteine pro...
|
|
WO/2010/133133A1 |
A synthetic method of 2-methyl-6-tert-butyl-4-dicyanomethylene-4H-pyran is disclosed. This method includes the following steps: (1) refluxing the solution of 2-methyl-6-tert-butyl-pyrone and malononitrile in acetic anhydride, monitoring ...
|
|
WO/2010/133473A1 |
The present invention relates to a method for producing 2-substituted 4-hydroxy-4-methyl tetrahydropyranoles by reacting 3-methylbut-3-en-1-ol (isoprenol) with the corresponding aldehydes in the presence of a strongly acidic cation excha...
|
|
WO/2010/133131A1 |
A synthetic method of 2-methyl-6-tert-butyl-4-dicyanomethylene-4H-pyran is disclosed. This method includes the following steps: (1). reacting pinacolone with boron trifluoride etherate to obtain 5,5-dimethyl-2,4-adipaldehyde-0,0-boron di...
|
|
WO/2010/127443A1 |
The present invention describes compounds of Formula I or a pharmaceutically acceptable salts or derivatives thereof. Compositions comprising compounds of Formula I are also described. The present invention further relates to a method of...
|
|
WO/2010/128324A1 |
The present invention provides compounds of formula (I), in which y, m, n, R1, R2 and Q are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them and their use in therapy.
|
|
WO/2010/125466A1 |
Methods for producing amrubicin and structural analogs thereof. The present invention encompasses synthetic pathways for the production of amrubicin (Formula I) and structural analogs thereof. The synthetic pathways of the present invent...
|
|
WO/2010/123016A1 |
Disclosed is a compound having a GPR40 agonistic activity and useful for use in a pharmaceutical composition or useful as an insulin secretion promoter or a prophylactic or therapeutic agent for diabetes. Extensive studies have been made...
|
|
WO/2010/122968A1 |
Disclosed is a compound useful as an anti-obesity agent. Studies have been made on compounds which have a DGAT1 inhibitory activity and are therefore promising active ingredients for pharmaceutical compositions for treating obesity, type...
|
|
WO/2010/119161A2 |
The invention relates to a compound having formula (I), the hydroxyacid form thereof, the pharmaceutically acceptable salts of the hydroxyacid and prodrugs and pharmaceutically acceptable solvates of the compound and the hydroxyacid form...
|
|
WO/2010/113813A1 |
Disclosed are: a base-generating agent which has a high sensitivity and a wide application range; and a photosensitive resin composition which has a wide range of application choices owing to the structure of a polymer precursor the reac...
|
|
WO2010110409A1 |
A pyrone derivative and a pyridone derivative which are intermediates for a novel anti-influenza drug; a process for producing these derivatives; and methods of using these derivatives.
|
|
WO/2010/102848A1 |
Compounds of Formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.
|
|
WO/2010/102003A2 |
In one aspect, the invention relates to compounds which are useful as as inhibitors of glycine type 1 transporter (GIyT1) activity; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and met...
|
|
WO/2010/098583A2 |
The present invention relates to a novel method for preparing statin compounds or salts thereof, which are useful in treating and preventing hyperlipidemia-related diseases, and to intermediate compounds used in same. The method of the p...
|
|
WO/2010/097374A1 |
The invention relates to the compounds of the general formula (I) wherein n, R1, R2, R3, R4, R5, R6, R7 and R8 are defined as described in the description, to enantiomers thereof, to diastereomers thereof, to mixtures and salts thereof, ...
|
|
WO/2010/095506A1 |
A liquid-crystalline compound which not only has a large negative value of permittivity anisotropy (Δε) but also has at least one property selected from stability to heat, light, etc., a high clear point, adequate refractive-index anis...
|
|
WO/2010/095768A1 |
The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppress...
|
|
WO/2010/093706A2 |
Provided herein is a method for chemically programmed vaccination. Methods include inducing a covalent-binding polyclonal antibody response in a subject and programming the polyclonal response with a targeting compound.
|
|
WO/2010/092154A1 |
The invention relates to substituted indanes and derivatives thereof, to physiologically acceptable salts and physiologically functional derivatives thereof, to the production thereof, to drugs containing at least one substituted indane ...
|
|
WO/2010/092153A1 |
The invention relates to substituted tetrahydronapthalenes, to derivatives thereof, to physiologically acceptable salts thereof, to physiologically functional derivatives, to the production thereof, to drugs containing at least one subst...
|
|
WO/2010/090305A1 |
Disclosed is an excellent agent for treatment or prevention of dementia, schizophrenia and the like, which has a serotonin 5-HT5A receptor modulating activity. An acylguanidine derivative represented by formula (I), wherein guanidine is ...
|
|
WO/2010/089211A1 |
Compounds of Formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.
|
|
WO/2010/090304A1 |
Disclosed is an excellent agent for treatment or prevention of dementia, schizophrenia and the like, which has a serotonin 5-HT5A receptor modulating activity. An acylguanidine derivative represented by formula (I), wherein guanidine is ...
|
|
WO/2010/089210A1 |
Compounds of Formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.
|
|
WO/2010/083732A1 |
N-acetylneuraminic acid compounds of formula I as follows, pharmaceutical composition, preparation method and uses thereof. The compounds can inhibit surface neuraminidase of influenza virus, thus can be used for resisting influenza viru...
|
|
WO/2010/081894A1 |
Compounds of formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.
|
|
WO/2010/082661A1 |
Disclosed is a composition for ameliorating postcibal hyperglycemia which comprises at least one member selected from the group consisting of 1,5-D-anhydroglucitol, 1,5-D-anhydrofructose and derivatives of the same. Also disclosed is a c...
|
|
WO/2010/081755A1 |
Compounds of formula (I), wherein the substituents are as defined in claim 1, are suitable for use as herbicides.
|
